The committee reported cases of hematologic malignancies in a follicular lymphoma study dubbed SYMPHONY-1.
March 9, 2026 02:16 PM EDT
Ipsen pulls cancer drug from market over safety risks
Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial.
The committee …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA warns ImmunityBio and Patrick Soon-Shiong over misleading Anktiva cancer drug ads on TV and podcast, claiming it can treat…
Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.
Exclusive: Drugs to treat stroke and schizophrenia patients could be hit if suppliers no longer see them as commercially viable
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
